INT37296

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1986
Last Reported 2011
Negated 4
Speculated 8
Reported most in Body
Documents 117
Total Number 128
Disease Relevance 62.51
Pain Relevance 27.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

enzyme binding (Esr1) DNA binding (Esr1) protein complex (Esr1)
cytoplasm (Esr1) lipid binding (Esr1) nucleus (Esr1)
Anatomy Link Frequency
vesicle 2
uterine 2
bar 1
exocrine pancreas 1
plasma cells 1
Esr1 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 186 100.00 Very High Very High Very High
Central nervous system 145 100.00 Very High Very High Very High
Glutamate 73 100.00 Very High Very High Very High
Osteoarthritis 61 100.00 Very High Very High Very High
cINOD 24 100.00 Very High Very High Very High
agonist 636 99.84 Very High Very High Very High
Bioavailability 48 99.84 Very High Very High Very High
rheumatoid arthritis 424 99.80 Very High Very High Very High
Migraine 28 99.76 Very High Very High Very High
Serotonin 249 99.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disease 1281 100.00 Very High Very High Very High
Breast Cancer 430 100.00 Very High Very High Very High
Osteoarthritis 63 100.00 Very High Very High Very High
Drug Induced Neurotoxicity 4 99.98 Very High Very High Very High
Stress 222 99.96 Very High Very High Very High
Rheumatoid Arthritis 427 99.80 Very High Very High Very High
Headache 55 99.76 Very High Very High Very High
Atherosclerosis 82 99.60 Very High Very High Very High
Neuropathic Pain 17 99.52 Very High Very High Very High
Stroke 75 99.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Raloxifene binds with high affinity to estrogen receptor (ER) ?
ER Binding (binds) of
1) Confidence 0.43 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC3009959 Disease Relevance 1.32 Pain Relevance 0.46
Raloxifene binds with high affinity to estrogen receptor (ER) ?
estrogen receptor Binding (binds) of
2) Confidence 0.43 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC3009959 Disease Relevance 1.32 Pain Relevance 0.46
We performed a case-control study with G594A and G325C polymorphisms to determine whether ESR1 is associated with migraine in our population.
ESR1 Binding (associated) of associated with migraine
3) Confidence 0.41 Published 2006 Journal Neuroreport Section Abstract Doc Link 16361951 Disease Relevance 0.61 Pain Relevance 0.67
Tissue specific differences in biologic outcomes are thought to be due, in part, to tissue specific differences in transcription factors which become activated upon binding of each oestrogen receptor (ER) by ligand [191-193].
ER Binding (binding) of
4) Confidence 0.39 Published 2011 Journal Biol Sex Differ Section Body Doc Link PMC3022636 Disease Relevance 0.40 Pain Relevance 0.05
In search of a patient- friendly pure anti-estrogen, we screened and identified an ER antagonist, CH4893237, which bound to ER with an IC50 value of 1.4 muM and, by oral administration, inhibited estrogen-stimulated uterine growth in ovariectomized mice.
ER Binding (bound) of in uterine associated with antagonist
5) Confidence 0.37 Published 2005 Journal Anticancer Drugs Section Abstract Doc Link 16027525 Disease Relevance 0.43 Pain Relevance 0.32
They include chemically diverse molecules that lack the steroid structure of estrogens, but possess a tertiary structure that allows them to bind to ER?
ER Binding (bind) of
6) Confidence 0.37 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.82 Pain Relevance 0.26
This SERM binds to both ER?
ER Binding (binds) of
7) Confidence 0.37 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0 Pain Relevance 0.15
selective than raloxifene, with an affinity for ER?
ER Binding (affinity) of
8) Confidence 0.37 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0 Pain Relevance 0.17
agonistic compounds and ER?
ER Binding (compounds) of
9) Confidence 0.35 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911889 Disease Relevance 1.39 Pain Relevance 0.65
in mice, an in vivo titration for ER?
ER Binding (titration) of
10) Confidence 0.35 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911889 Disease Relevance 0.21 Pain Relevance 0.31
Estrogens bind both estrogen receptor (ER)?
ER Binding (bind) of
11) Confidence 0.34 Published 2010 Journal Arthritis Res Ther Section Abstract Doc Link PMC2911889 Disease Relevance 0.98 Pain Relevance 0.48
Estrogens bind both estrogen receptor (ER)?
estrogen receptor Binding (bind) of
12) Confidence 0.34 Published 2010 Journal Arthritis Res Ther Section Abstract Doc Link PMC2911889 Disease Relevance 0.98 Pain Relevance 0.48
We have recently shown that signaling through ER?
ER Binding (signaling) of
13) Confidence 0.33 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC3009959 Disease Relevance 1.32 Pain Relevance 0.44
Similar interactions have been described previously for ER interaction with the thyroid receptor [31].
ER Binding (interaction) of in thyroid
14) Confidence 0.33 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2432036 Disease Relevance 0.18 Pain Relevance 0.04
Mechanistic studies revealed that the E2-ER complex was not likely to be competent for PPAR?
E2-ER Binding (complex) of
15) Confidence 0.32 Published 2010 Journal PPAR Research Section Body Doc Link PMC2943125 Disease Relevance 0.10 Pain Relevance 0
‚ with a slight higher affinity for ER?.
ER Binding (affinity) of
16) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0 Pain Relevance 0.14
devoid of activity on ER?
ER Binding (activity) of
17) Confidence 0.31 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2724541 Disease Relevance 0 Pain Relevance 0.13
Fulvestrant, on the other hand, binds and degrades ER, thereby acting as a pure anti-estrogen without partial agonist activity.
ER Binding (binds) of associated with agonist
18) Confidence 0.31 Published 2005 Journal Anticancer Drugs Section Abstract Doc Link 16027525 Disease Relevance 0.45 Pain Relevance 0.30
In search of a patient- friendly pure anti-estrogen, we screened and identified an ER antagonist, CH4893237, which bound to ER with an IC50 value of 1.4 muM and, by oral administration, inhibited estrogen-stimulated uterine growth in ovariectomized mice.
ER Binding (bound) of in uterine associated with antagonist
19) Confidence 0.31 Published 2005 Journal Anticancer Drugs Section Abstract Doc Link 16027525 Disease Relevance 0.43 Pain Relevance 0.32
However, all bar one of the associated markers lie not in ESR1 itself but in an open reading frame gene C6orf97, which is currently of unknown expression and function.
ESR1 Neg (not) Binding (lie) of in bar
20) Confidence 0.31 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592817 Disease Relevance 0.14 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox